ReviewThe FEBS journal2026
Proteolysis at the extracellular matrix interface: Molecular architects and regulators in health and disease.
Review in The FEBS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- When proteases reshape barriers: Basement membrane remodelling in development, wound healing and tumour progression.The FEBS journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The extracellular matrix (ECM) is a dynamic and multifaceted scaffold that orchestrates tissue architecture, signalling and cell behaviour in multicellular organisms. Its function arises from the interplay between composition, three-dimensional organisation and mechanics, together with the tightly regulated activity of proteolytic enzymes and cell surface receptors. Cluster of differentiation (CD) molecules function as regulators at the cell-matrix interface by directing adhesion, migration, immune surveillance and the localisation of proteases within pericellular niches. Cathepsins, along with matrix metalloproteinases, ADAM and ADAMTS sheddases, orchestrate ECM turnover, basement membrane and interstitial remodelling, and the generation of bioactive fragments that influence cell fate and signalling. Disruption of these networks shifts tissues towards fibrosis, defective development, chronic inflammation, vascular pathologies and cancer. This review integrates foundational principles with recent discoveries to map the molecular architects and regulators of the matrix in health and disease, emphasising how composition and mechanics interact with protease-driven turnover and receptor-mediated sensing. Finally, we outline emerging therapeutic strategies that restore matrix balance through targeted modulation of protease activity, engineering of ECM-mimetic scaffolds with programmable mechanics and degradability, and tuning of CD-mediated signalling to promote regeneration and resolution.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.